"Challenges in the Treatment of Bipolar Disorders: Looking Ahead"
Lakshmi N. Yatham is a Professor and Head of the Department of Psychiatry and Director of the Institute of Mental Health at the University of British Columbia in Vancouver, Canada. He is also the Regional Head of Psychiatry and Regional Program Medical Director for Mental Health and Addictions at Vancouver Coastal Health and Providence Healthcare. He has an executive MBA in health care from the Sauder School of Business. Dr. Yatham has held leadership positions for national and international professional organizations including the President of the International Society for Bipolar Disorders, the Secretary for the World Federation of Societies of Biological Psychiatry (WFSBP), and he is now the President of the WFSBP and the Editor in Chief for the Canadian Journal of Psychiatry. Dr. Yatham was listed in the Clarivate Analytics 2017 to 2020 reports and Thomson Reuters’ reports on “World’s Most Influential Scientific Minds -2014 and 2015” as one of the most highly cited researchers (publications with top 1% of citations) in psychiatry/psychology in the world based on research published since 2002.
Dr. Yatham’s major areas of research interest include neurobiology and treatment of bipolar disorder and major depression. Dr. Yatham has received a number of awards during his career including the Michael Smith Foundation Senior Scholar Award and NARSAD Young and Independent Investigator Awards for research, Distinguished Medical Research Lecturer Award from the Faculty of Medicine at UBC for his research contributions, Mogen Schou Award for international education and advocacy on bipolar disorder from the International Society for Bipolar Disorders (ISBD), South Asian Forum Internationale Award for his contributions to psychiatric research in the developing world, Heinz Lehman Award as well as the Canadian College of Neuropsychopharmacology Medal for his contributions to psychopharmacology, John M Cleghorn Award for excellence in research and leadership from the Canadian Psychiatric Association, Frank and Kupfer Award from the ISBD for distinctive and sustained contributions to the field of bipolar disorder, Gerald L Klerman Award from Depression and Bipolar Support Alliance in the USA for significant contribution towards advancing causes, diagnosis and treatment of mood disorders and the Colvin Research Prize in Mood Disorders from the Brain and Behaviour Foundation in the USA for his outstanding contributions to research in mood disorders. Dr. Yatham’s work has been funded by many peer-reviewed funding agencies such as the Canadian Institutes of Health Research (CIHR), Canadian Psychiatric Research Foundation, Stanley Foundation, and National Alliance for Research on Schizophrenia and Depression, USA. He is a member of the College of Reviewers of Canadian Institutes of Health Research (CIHR), was a chair of the Michael Smith Foundation Clinical Scholars Committee and has been a reviewer and a committee member of other peer reviewed funding agencies such as the CIHR. He is a member of the Scientific Advisory Board of the International Bipolar Foundation, Depression and Bipolar Support Alliance and Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital in Boston.
Dr. Yatham has a google scholar h-index of 81, and he has published over 350 papers in peer-reviewed international journals including in high impact journals such as Lancet Psychiatry, Molecular Psychiatry, Archives of General Psychiatry, American Journal of Psychiatry, World Psychiatry, Biological Psychiatry and British Journal of Psychiatry. He has edited books and written a number of book chapters including a chapter on Treatment of mood disorders for the current 10th edition of the Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. Dr. Yatham is a sought after speaker and has presented his research work at numerous international conferences. He has edited journal supplements and top selling books on bipolar disorder. He co-led the development of Canadian guidelines for treatment of bipolar disorder in 1997 and his group revised the guidelines for 2005 with International Commentaries. The CANMAT guidelines are widely used for treatment of bipolar disorder around the world as these are updated and published every 3 years in Bipolar Disorders Journal. These are highly cited with the most recent full version published in 2018 as CANMAT and ISBD guidelines in Bipolar Disorders Journal has already received over 500 citations. He is the Chair of the bipolar group of the Canadian Network for Mood and Anxiety Treatments (CANMAT), and is actively involved at a national and international level in continuing medical education and public education on diagnosis and treatment of bipolar disorder for psychiatrists, family physicians, and the general public. In addition to being the Editor-in-Chief for the Canadian Journal of Psychiatry, he sits on the editorial boards of a number of journals including Bipolar Disorders, World Journal of Biological Psychiatry, Journal of Affective Disorders, Acta Neuropsychiatrica, Australia and New Zealand Journal of Psychiatry, Human Psychopharmacology etc.
"Challenges in the Treatment of Bipolar Disorders: Looking Ahead"
Lakshmi N. Yatham is a Professor and Head of the Department of Psychiatry and Director of the Institute of Mental Health at the University of British Columbia in Vancouver, Canada. He is also the Regional Head of Psychiatry and Regional Program Medical Director for Mental Health and Addictions at Vancouver Coastal Health and Providence Healthcare. He has an executive MBA in health care from the Sauder School of Business. Dr. Yatham has held leadership positions for national and international professional organizations including the President of the International Society for Bipolar Disorders, the Secretary for the World Federation of Societies of Biological Psychiatry (WFSBP), and he is now the President of the WFSBP and the Editor in Chief for the Canadian Journal of Psychiatry. Dr. Yatham was listed in the Clarivate Analytics 2017 to 2020 reports and Thomson Reuters’ reports on “World’s Most Influential Scientific Minds -2014 and 2015” as one of the most highly cited researchers (publications with top 1% of citations) in psychiatry/psychology in the world based on research published since 2002.
Dr. Yatham’s major areas of research interest include neurobiology and treatment of bipolar disorder and major depression. Dr. Yatham has received a number of awards during his career including the Michael Smith Foundation Senior Scholar Award and NARSAD Young and Independent Investigator Awards for research, Distinguished Medical Research Lecturer Award from the Faculty of Medicine at UBC for his research contributions, Mogen Schou Award for international education and advocacy on bipolar disorder from the International Society for Bipolar Disorders (ISBD), South Asian Forum Internationale Award for his contributions to psychiatric research in the developing world, Heinz Lehman Award as well as the Canadian College of Neuropsychopharmacology Medal for his contributions to psychopharmacology, John M Cleghorn Award for excellence in research and leadership from the Canadian Psychiatric Association, Frank and Kupfer Award from the ISBD for distinctive and sustained contributions to the field of bipolar disorder, Gerald L Klerman Award from Depression and Bipolar Support Alliance in the USA for significant contribution towards advancing causes, diagnosis and treatment of mood disorders and the Colvin Research Prize in Mood Disorders from the Brain and Behaviour Foundation in the USA for his outstanding contributions to research in mood disorders. Dr. Yatham’s work has been funded by many peer-reviewed funding agencies such as the Canadian Institutes of Health Research (CIHR), Canadian Psychiatric Research Foundation, Stanley Foundation, and National Alliance for Research on Schizophrenia and Depression, USA. He is a member of the College of Reviewers of Canadian Institutes of Health Research (CIHR), was a chair of the Michael Smith Foundation Clinical Scholars Committee and has been a reviewer and a committee member of other peer reviewed funding agencies such as the CIHR. He is a member of the Scientific Advisory Board of the International Bipolar Foundation, Depression and Bipolar Support Alliance and Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital in Boston.
Dr. Yatham has a google scholar h-index of 81, and he has published over 350 papers in peer-reviewed international journals including in high impact journals such as Lancet Psychiatry, Molecular Psychiatry, Archives of General Psychiatry, American Journal of Psychiatry, World Psychiatry, Biological Psychiatry and British Journal of Psychiatry. He has edited books and written a number of book chapters including a chapter on Treatment of mood disorders for the current 10th edition of the Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. Dr. Yatham is a sought after speaker and has presented his research work at numerous international conferences. He has edited journal supplements and top selling books on bipolar disorder. He co-led the development of Canadian guidelines for treatment of bipolar disorder in 1997 and his group revised the guidelines for 2005 with International Commentaries. The CANMAT guidelines are widely used for treatment of bipolar disorder around the world as these are updated and published every 3 years in Bipolar Disorders Journal. These are highly cited with the most recent full version published in 2018 as CANMAT and ISBD guidelines in Bipolar Disorders Journal has already received over 500 citations. He is the Chair of the bipolar group of the Canadian Network for Mood and Anxiety Treatments (CANMAT), and is actively involved at a national and international level in continuing medical education and public education on diagnosis and treatment of bipolar disorder for psychiatrists, family physicians, and the general public. In addition to being the Editor-in-Chief for the Canadian Journal of Psychiatry, he sits on the editorial boards of a number of journals including Bipolar Disorders, World Journal of Biological Psychiatry, Journal of Affective Disorders, Acta Neuropsychiatrica, Australia and New Zealand Journal of Psychiatry, Human Psychopharmacology etc.
“Evidence Based Mental Health in the Real World: Promises, Challenges and Future Directions”
Andrea Cipriani is Professor of Psychiatry and NIHR Research Professor at the Department of Psychiatry, University of Oxford, and Honorary Consultant Psychiatrist at Oxford Health NHS Foundation Trust. His main interest in psychiatry is evidence-based mental health and his research focuses on the evaluation of treatments in psychiatry, mainly major depression, bipolar disorder and schizophrenia. His research in the methodology of evidence synthesis has now a specific focus on individual patient data network meta-analysis and data science, trying to assess the validity, breadth, structure and interpretation of innovative statistical and machine learning approaches to better inform the decision-making process between patients and clinicians and personalise treatment indications in routine clinical care. Professor Cipriani is currently the Director of the NIHR Oxford cognitive health Clinical Research Facility, Lead of the Digital and Informatics Theme of the Oxford Health Biomedical Research Centre and the Editor in Chief of Evidence-Based Mental Health (https://ebmh.bmj.com/).
“Evidence Based Mental Health in the Real World: Promises, Challenges and Future Directions”
Andrea Cipriani is Professor of Psychiatry and NIHR Research Professor at the Department of Psychiatry, University of Oxford, and Honorary Consultant Psychiatrist at Oxford Health NHS Foundation Trust. His main interest in psychiatry is evidence-based mental health and his research focuses on the evaluation of treatments in psychiatry, mainly major depression, bipolar disorder and schizophrenia. His research in the methodology of evidence synthesis has now a specific focus on individual patient data network meta-analysis and data science, trying to assess the validity, breadth, structure and interpretation of innovative statistical and machine learning approaches to better inform the decision-making process between patients and clinicians and personalise treatment indications in routine clinical care. Professor Cipriani is currently the Director of the NIHR Oxford cognitive health Clinical Research Facility, Lead of the Digital and Informatics Theme of the Oxford Health Biomedical Research Centre and the Editor in Chief of Evidence-Based Mental Health (https://ebmh.bmj.com/).
John M. Kane, MD. is the Senior Vice President for Behavioural Health Services at Northwell Health in New Hyde Park, New York. He is Chairman of the Department of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, New York. Additionally, he is Professor and Chairman of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Dr. Kane earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.
Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society and the Schizophrenia International Research Society.
Dr. Kane has been the principal investigator for research projects focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 600 peer-reviewed papers and serves on the editorial boards of numerous journals.
John M. Kane, MD. is the Senior Vice President for Behavioural Health Services at Northwell Health in New Hyde Park, New York. He is Chairman of the Department of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, New York. Additionally, he is Professor and Chairman of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Dr. Kane earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.
Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society and the Schizophrenia International Research Society.
Dr. Kane has been the principal investigator for research projects focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 600 peer-reviewed papers and serves on the editorial boards of numerous journals.
“Artificial Intelligence in the Pharmacological Treatment of Psychiatric Conditions”
Dr. Roger McIntyre, MD, FRCPC, is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.
Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre is also Clinical Professor State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA and Clinical Professor Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA. Dr. McIntyre is the founder of the Canadian Rapid Treatment Centre of Excellence (CRTCE).
Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019 and 2020 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has published more than 700 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre is the lead author for the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
“Artificial Intelligence in the Pharmacological Treatment of Psychiatric Conditions”
Dr. Roger McIntyre, MD, FRCPC, is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.
Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre is also Clinical Professor State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA and Clinical Professor Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA. Dr. McIntyre is the founder of the Canadian Rapid Treatment Centre of Excellence (CRTCE).
Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019 and 2020 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has published more than 700 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre is the lead author for the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
Meet the Experts: "Advances in the understanding and management of treatment resistance in bipolar disorder"
Eduard Vieta is Professor of Psychiatry and Chair at the University of Barcelona and Head of the Department of Psychiatry and Psychology at the Hospital Clinic, where he also leads the Bipolar and Depressive Disorders Program in Barcelona, Catalonia, Spain. His unit is one of the worldwide leaders in clinical care, teaching and research on affective disorders. Dr. Vieta is also the current Scientific Director of the Spanish Research Network on Mental Health (CIBERSAM). He has received the Aristotle award (2005), the Mogens Schou award (2007), the Strategic Research award of the Spanish Society of Biological Psychiatry (2009), the Official College of Physicians award to Professional Excellence (2011), the Colvin Price on Outstanding Achievement in Mood Disorders Research by the Brain and Behaviour Research Foundation (2012), the Clinical Neuroscience Lilly award by the International College of Neuropsychopharmacology (CINP 2014), the Simon Bolivar Award (American Psychiatric Association 2017) and the Research Price of the World Federation of Societies of Biological Psychiatry (WFSBP, 2017). He has been named twice best psychiatrist in Spain (Monitor sanitario, El Español), honorary member of the Spanish Society of Biological Psychiatry, and Doctor Honoris Causa by the University of Valencia. He has authored more than 950 original articles, 450 book chapters and 45 books. His h index is 134 and has over 66.000 citations (Google Scholar), which makes him the most cited scientist worldwide in the field of bipolar disorder over the last 8 years and one of the world’s most influential scientific minds, according to Clarivate Analytics ranking (Highly Cited). His papers have over 600.000 downloads. Furthermore, he is Editor-in-Chief of European Neuropsychopharmacology and has served as invited professor at McLean Hospital and Harvard University and as neuroscience scientific advisor to the European Presidency.
Meet the Experts: "Advances in the understanding and management of treatment resistance in bipolar disorder"
Eduard Vieta is Professor of Psychiatry and Chair at the University of Barcelona and Head of the Department of Psychiatry and Psychology at the Hospital Clinic, where he also leads the Bipolar and Depressive Disorders Program in Barcelona, Catalonia, Spain. His unit is one of the worldwide leaders in clinical care, teaching and research on affective disorders. Dr. Vieta is also the current Scientific Director of the Spanish Research Network on Mental Health (CIBERSAM). He has received the Aristotle award (2005), the Mogens Schou award (2007), the Strategic Research award of the Spanish Society of Biological Psychiatry (2009), the Official College of Physicians award to Professional Excellence (2011), the Colvin Price on Outstanding Achievement in Mood Disorders Research by the Brain and Behaviour Research Foundation (2012), the Clinical Neuroscience Lilly award by the International College of Neuropsychopharmacology (CINP 2014), the Simon Bolivar Award (American Psychiatric Association 2017) and the Research Price of the World Federation of Societies of Biological Psychiatry (WFSBP, 2017). He has been named twice best psychiatrist in Spain (Monitor sanitario, El Español), honorary member of the Spanish Society of Biological Psychiatry, and Doctor Honoris Causa by the University of Valencia. He has authored more than 950 original articles, 450 book chapters and 45 books. His h index is 134 and has over 66.000 citations (Google Scholar), which makes him the most cited scientist worldwide in the field of bipolar disorder over the last 8 years and one of the world’s most influential scientific minds, according to Clarivate Analytics ranking (Highly Cited). His papers have over 600.000 downloads. Furthermore, he is Editor-in-Chief of European Neuropsychopharmacology and has served as invited professor at McLean Hospital and Harvard University and as neuroscience scientific advisor to the European Presidency.
Meet the Experts: "Building evidence for sequenced depression treatment"
Prof Toshi A. Furukawa, MD, PhD is currently Professor of the Departments of Health Promotion and Human Behavior, and of Clinical Epidemiology at Kyoto University Graduate School of Medicine / School of Public Health. Prof Furukawa’s major areas of interest and expertise include clinical epidemiology, evidence synthesis, and clinical psycho-pharmacology and cognitive-behavior therapy in mood and anxiety disorders. He is author and co-author of over 450 peer-reviewed articles. His bio was featured in the Lancet Psychiatry in May 2020 (https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30157-7/fulltext).
Meet the Experts: "Building evidence for sequenced depression treatment"
Prof Toshi A. Furukawa, MD, PhD is currently Professor of the Departments of Health Promotion and Human Behavior, and of Clinical Epidemiology at Kyoto University Graduate School of Medicine / School of Public Health. Prof Furukawa’s major areas of interest and expertise include clinical epidemiology, evidence synthesis, and clinical psycho-pharmacology and cognitive-behavior therapy in mood and anxiety disorders. He is author and co-author of over 450 peer-reviewed articles. His bio was featured in the Lancet Psychiatry in May 2020 (https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30157-7/fulltext).
Professor Ya Mei Bai, M.D.,Ph.D.
Chief, Department of Psychiatry,
National Yang Ming Chiao Tung University; Chief, Department of General Psychiatry, Taipei Veterans General Hospital, Taiwan; Deputy Director, Faculty of Medicine,
National Yang-Ming University, Taipei, Taiwan
Professor Bai‘s main clinical and academic interests include tardive dyskinesia, metabolic syndrome, and inflammatory research in schizophrenia, depressive disorder and bipolar disorder, including clinical cohort study, psycho-epidemiology study of Taiwan National health insurance data, psychopharmacology, and neuro-imaging studies. She has published more than 280 papers in the international SCI journals, including many papers in American Journal of Psychiatry, Journal of Clinical Psychiatry, schizophrenia research, Journal of affective disorder, bipolar disorders, Journal of Clinical psychopharmacology. She has received many honors and awards including Dr. Paul Janssen Research Award and Bipolar disorder research Award, GSK depression and anxiety research Award by -Taiwan Society of Psychiatry and Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology, ECNP Travel Award, Travel Award BP/NP OSAKA, the Excellent Teacher of the year of National Yang-Ming University for more than 15 years, and the Teacher of the Year by the Taipei Veterans General Hospital.
Professor Ya Mei Bai, M.D.,Ph.D.
Chief, Department of Psychiatry,
National Yang Ming Chiao Tung University; Chief, Department of General Psychiatry, Taipei Veterans General Hospital, Taiwan; Deputy Director, Faculty of Medicine,
National Yang-Ming University, Taipei, Taiwan
Professor Bai‘s main clinical and academic interests include tardive dyskinesia, metabolic syndrome, and inflammatory research in schizophrenia, depressive disorder and bipolar disorder, including clinical cohort study, psycho-epidemiology study of Taiwan National health insurance data, psychopharmacology, and neuro-imaging studies. She has published more than 280 papers in the international SCI journals, including many papers in American Journal of Psychiatry, Journal of Clinical Psychiatry, schizophrenia research, Journal of affective disorder, bipolar disorders, Journal of Clinical psychopharmacology. She has received many honors and awards including Dr. Paul Janssen Research Award and Bipolar disorder research Award, GSK depression and anxiety research Award by -Taiwan Society of Psychiatry and Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology, ECNP Travel Award, Travel Award BP/NP OSAKA, the Excellent Teacher of the year of National Yang-Ming University for more than 15 years, and the Teacher of the Year by the Taipei Veterans General Hospital.
Yu-Tao Xiang, MD, PhD, Professor, Unit of Psychiatry, Faculty of Health Sciences, University of Macau
Prof. Xiang obtained his Bachelor and Master degrees in the Capital Medical University, China, obtained his PhD degree in the Chinese University of Hong Kong Faculty of Medicine, and then received post-doctoral training at University of Maryland School of Medicine in the US.
Prof. Xiang has authored or co-authored over 500 papers in international (SCI/SSCI) journals, including Lancet, Lancet Psychiatry, and JAMA Psychiatry, with the total citations of more than 13,000. He has received over ten international research awards for his work, such as the Outstanding Young Psychiatrist Award in Developing Countries released by the World Psychiatric Association (WPA)
Yu-Tao Xiang, MD, PhD, Professor, Unit of Psychiatry, Faculty of Health Sciences, University of Macau
Prof. Xiang obtained his Bachelor and Master degrees in the Capital Medical University, China, obtained his PhD degree in the Chinese University of Hong Kong Faculty of Medicine, and then received post-doctoral training at University of Maryland School of Medicine in the US.
Prof. Xiang has authored or co-authored over 500 papers in international (SCI/SSCI) journals, including Lancet, Lancet Psychiatry, and JAMA Psychiatry, with the total citations of more than 13,000. He has received over ten international research awards for his work, such as the Outstanding Young Psychiatrist Award in Developing Countries released by the World Psychiatric Association (WPA)
Prof Tao Li, M.D., PhD, is a professor of Psychiatry in Zhejiang University and Sichuan University. Dr Li received her M.D at West China University of Medical Sciences in China and her PhD at King’s College London in UK. She served as the chair of mental health center in West China Hospital of Sichuan University for more than 10 years, and now is working as the president of Affiliated Mental Health Center & Hangzhou Seventh People's Hospital in Zhejiang University School of Medicine. She has worked on psychiatric research mainly in the following two areas. Firstly, her research is mainly focused on identifying the causes and biomarkers of psychiatric disorders, and to develop clinically rational means to optimize the treatment in mental disorders in order to ensure maximum efficacy with minimal adverse effects. Secondly, she has been working on the development of mental health services for local communities, such as mental crisis intervention after the 2008 Wenchuan earthquake in Sichuan, and promoting mental health care and conserving medical resources for patients with physical diseases in general hospitals. Prof Li received various honours and awards, including the National Outstanding Young Scientist Award, Chinese Outstanding Young Female Scientist Award, and the CMB Distinguished Professor Award etc. She published more than 300 peer-reviewed scientific publications, including papers on Molecular Psychiatry, Am J Psychiatry and JAMA Psychiatry as first and /or corresponding author. She is the Vice President, Chinese Society of Psychiatry, and the Vice President, Pacific Rim College of Psychiatrists.
Prof Tao Li, M.D., PhD, is a professor of Psychiatry in Zhejiang University and Sichuan University. Dr Li received her M.D at West China University of Medical Sciences in China and her PhD at King’s College London in UK. She served as the chair of mental health center in West China Hospital of Sichuan University for more than 10 years, and now is working as the president of Affiliated Mental Health Center & Hangzhou Seventh People's Hospital in Zhejiang University School of Medicine. She has worked on psychiatric research mainly in the following two areas. Firstly, her research is mainly focused on identifying the causes and biomarkers of psychiatric disorders, and to develop clinically rational means to optimize the treatment in mental disorders in order to ensure maximum efficacy with minimal adverse effects. Secondly, she has been working on the development of mental health services for local communities, such as mental crisis intervention after the 2008 Wenchuan earthquake in Sichuan, and promoting mental health care and conserving medical resources for patients with physical diseases in general hospitals. Prof Li received various honours and awards, including the National Outstanding Young Scientist Award, Chinese Outstanding Young Female Scientist Award, and the CMB Distinguished Professor Award etc. She published more than 300 peer-reviewed scientific publications, including papers on Molecular Psychiatry, Am J Psychiatry and JAMA Psychiatry as first and /or corresponding author. She is the Vice President, Chinese Society of Psychiatry, and the Vice President, Pacific Rim College of Psychiatrists.
Takahiro A. Kato, M.D., PhD. currently works as a clinical psychiatrist at the Kyushu University Hospital, and as an associate professor and Group Leader of the Molecular Psychiatry Unit, Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Japan. His a translational researcher bridging the huge gap between mind and brain, especially focusing on microglia, depression, hikikomori, and psychoanalysis. He is also Secretary of the World Psychiatric Association section of “Urban Mental Health” and a trainer and founding member, Mental Health First Aid - Japan. His works have been highlighted in Lancet, Lancet Psychiatry, American Journal of Psychiatry,World Psychiatry, etc...
Takahiro A. Kato, M.D., PhD. currently works as a clinical psychiatrist at the Kyushu University Hospital, and as an associate professor and Group Leader of the Molecular Psychiatry Unit, Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Japan. His a translational researcher bridging the huge gap between mind and brain, especially focusing on microglia, depression, hikikomori, and psychoanalysis. He is also Secretary of the World Psychiatric Association section of “Urban Mental Health” and a trainer and founding member, Mental Health First Aid - Japan. His works have been highlighted in Lancet, Lancet Psychiatry, American Journal of Psychiatry,World Psychiatry, etc...
Dr. Shih-Ku Lin graduated from Kaohsiung Medical University in 1981, and received his psychiatric residency training in Taipei City Psychiatric Center (TCPC). After completing the training and acquired Board Certified Psychiatrist qualification, he had his fellowship of child psychiatry at Kansas University Medical Center in 1988. In 1993, he was appointed as the Chief of Department of Addiction Science at TCPC and has led this department for 11 years. He then chaired of the Department of Psychiatry, Taipei City Hospital and Psychiatric Center and also was adjunct associate professor, College of Medicine, Taipei Medical University. He retired from this hospital in July 2020 and moved to the Linkou Chang Gung Memorial Hospital.
Since his residency, he followed Professor Wen-Ho Chang in academic researches and participated in the founding of Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) and served the first secretary of this Society in 2002 and served the term of president 2016-2019. Dr. Lin also founded Taiwanese Society of Addiction and served the first President in 2008. Currently he is the vice-President of International College of Neuropsychopharmacology (CINP) and Asian College of Neuropsychopharmacology (AsCNP).
Dr Lin’s research interest includes psychopharmacology, focusing on ethnic differences in pharmacokinetics and new drug clinical trials. Currently he also plays a major role in the consortium of Research on Asian Prescription Pattern (REAP), which is the largest and the longest lasting international collaborative research in psychiatry in Asia. In addictive disorders, his groups focus on heroin dependence, methamphetamine-induced psychosis and ketamine use disorder, cover from genetic studies to clinical interventions. He also has more than twenty years’ experiences in clinical trials, mostly for phase II or III global and regional new psychotropic drug development. Dr Lin has published more than one hundred and fifty peer reviewed papers and has reviewed articles for many international journals.
Dr. Shih-Ku Lin graduated from Kaohsiung Medical University in 1981, and received his psychiatric residency training in Taipei City Psychiatric Center (TCPC). After completing the training and acquired Board Certified Psychiatrist qualification, he had his fellowship of child psychiatry at Kansas University Medical Center in 1988. In 1993, he was appointed as the Chief of Department of Addiction Science at TCPC and has led this department for 11 years. He then chaired of the Department of Psychiatry, Taipei City Hospital and Psychiatric Center and also was adjunct associate professor, College of Medicine, Taipei Medical University. He retired from this hospital in July 2020 and moved to the Linkou Chang Gung Memorial Hospital.
Since his residency, he followed Professor Wen-Ho Chang in academic researches and participated in the founding of Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) and served the first secretary of this Society in 2002 and served the term of president 2016-2019. Dr. Lin also founded Taiwanese Society of Addiction and served the first President in 2008. Currently he is the vice-President of International College of Neuropsychopharmacology (CINP) and Asian College of Neuropsychopharmacology (AsCNP).
Dr Lin’s research interest includes psychopharmacology, focusing on ethnic differences in pharmacokinetics and new drug clinical trials. Currently he also plays a major role in the consortium of Research on Asian Prescription Pattern (REAP), which is the largest and the longest lasting international collaborative research in psychiatry in Asia. In addictive disorders, his groups focus on heroin dependence, methamphetamine-induced psychosis and ketamine use disorder, cover from genetic studies to clinical interventions. He also has more than twenty years’ experiences in clinical trials, mostly for phase II or III global and regional new psychotropic drug development. Dr Lin has published more than one hundred and fifty peer reviewed papers and has reviewed articles for many international journals.
Dr. Ducharme is a Neuropsychiatrist and a clinician-scientist at the Douglas Mental Health University Institute and The Neuro (MNI). He is specialized in frontotemporal dementia, and the interface between psychiatric disorders and dementia. His research program uses advanced neuroimaging techniques to develop diagnostic biomarkers for frontotemporal dementia. Dr. Ducharme holds a Junior 2 clinician-scientist award from the FRQS and his research projects are funded by the CIHR, Weston Brain Institute, JPND, Medteq and Prompt-AI. He is in charge of several innovative clinical trials on dementia at The Neuro and he is the author of over 70 scientific articles and 7 book chapters. Dr. Ducharme is the director of the McGill Division of Geriatric Psychiatry & Neuropsychiatry and the director of the American Neuropsychiatric Association committee on research.
Dr. Ducharme is a Neuropsychiatrist and a clinician-scientist at the Douglas Mental Health University Institute and The Neuro (MNI). He is specialized in frontotemporal dementia, and the interface between psychiatric disorders and dementia. His research program uses advanced neuroimaging techniques to develop diagnostic biomarkers for frontotemporal dementia. Dr. Ducharme holds a Junior 2 clinician-scientist award from the FRQS and his research projects are funded by the CIHR, Weston Brain Institute, JPND, Medteq and Prompt-AI. He is in charge of several innovative clinical trials on dementia at The Neuro and he is the author of over 70 scientific articles and 7 book chapters. Dr. Ducharme is the director of the McGill Division of Geriatric Psychiatry & Neuropsychiatry and the director of the American Neuropsychiatric Association committee on research.
Professor Mark Walterfang has worked as a consultant neuropsychiatrist at the Royal Melbourne Hospital for more than 20 years, having completed specialist training at Neuropsychiatry, RMH, and his PhD at the Melbourne Neuropsychiatry Centre, focusing on neuroimaging. He is completing a second research doctorate in Niemann-Pick type C disease, having managed adolescent and adult patients with this illness at Neuropsychiatry since 2000.
Niemann Pick Type C: Common and Uncommon Questions
The diagnosis of the rare disorder NPC can be unexpected for patients, families and clinicians, and brings with it a wealth of questions about the disease, its effects on patients and families, and individuals. This talk will weave together clinical experience and research on NPC, with the aim of answering some of the common, and less common, questions on this disorder.
Professor Mark Walterfang has worked as a consultant neuropsychiatrist at the Royal Melbourne Hospital for more than 20 years, having completed specialist training at Neuropsychiatry, RMH, and his PhD at the Melbourne Neuropsychiatry Centre, focusing on neuroimaging. He is completing a second research doctorate in Niemann-Pick type C disease, having managed adolescent and adult patients with this illness at Neuropsychiatry since 2000.
Niemann Pick Type C: Common and Uncommon Questions
The diagnosis of the rare disorder NPC can be unexpected for patients, families and clinicians, and brings with it a wealth of questions about the disease, its effects on patients and families, and individuals. This talk will weave together clinical experience and research on NPC, with the aim of answering some of the common, and less common, questions on this disorder.
Dr. Citrome is clinical professor of psychiatry and behavioral sciences at New York Medical College in Valhalla, New York, clinical professor of psychiatry at SUNY Upstate Medical University, and adjunct clinical professor of psychiatry, Icahn School of Medicine at Mount Sinai in New York City, New York. In addition to his academic positions, he has a private practice in psychiatry in Pomona, New York and is a volunteer consultant to the Assertive Community Treatment team/Mental Health Association of Rockland County. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American Society of Clinical Psychopharmacology where he currently serves as President. In 2019 he received the New York Medical College Faculty Author Award for “First Authorship Who Published in the Most Open Access Journals (Web of Science),” and in 2018 was recognized as the Voluntary Faculty Teacher of the Year, Department of Psychiatry and Behavioral Sciences, New York Medical College.
Dr. Citrome obtained his MD degree from the McGill University Faculty of Medicine in 1983 and his MPH degree from the Columbia School of Public Health in 1996. His immediate prior position was as the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, where he worked from 1994 through 2010 and achieved the rank of Professor of Psychiatry at the New York University School of Medicine.
Dr. Citrome is currently a consultant in clinical trial design and interpretation. He is a frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of number needed to treat and number needed to harm, and has lectured throughout the Americas, Europe, Asia, and Australasia. His main interests include schizophrenia, bipolar disorder, and major depressive disorder. He is author or coauthor of over 550 research reports, reviews, and chapters in the scientific literature. Dr. Citrome is editor emeritus, International Journal of Clinical Practice where he was editor-in-chief 2013-2019; psychiatry topic editor for Clinical Therapeutics; editor for the American Society of Clinical Psychopharmacology Corner in the Journal of Clinical Psychiatry; section editor for psychopharmacology for Current Psychiatry; and also serves as an editorial board member for CNS Spectrums, Expert Review of Neurotherapeutics, Neurology and Therapy, Clinical Psychopharmacology and Neuroscience, Annals of Clinical Psychiatry, Expert Opinion on Drug Safety, Current Drug Safety, Schizophrenia Research and Treatment, Postgraduate Medicine, Journal of Clinical Psychopharmacology, Clinical Practice, Medscape Psychiatry & Mental Health.
Dr. Citrome is clinical professor of psychiatry and behavioral sciences at New York Medical College in Valhalla, New York, clinical professor of psychiatry at SUNY Upstate Medical University, and adjunct clinical professor of psychiatry, Icahn School of Medicine at Mount Sinai in New York City, New York. In addition to his academic positions, he has a private practice in psychiatry in Pomona, New York and is a volunteer consultant to the Assertive Community Treatment team/Mental Health Association of Rockland County. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American Society of Clinical Psychopharmacology where he currently serves as President. In 2019 he received the New York Medical College Faculty Author Award for “First Authorship Who Published in the Most Open Access Journals (Web of Science),” and in 2018 was recognized as the Voluntary Faculty Teacher of the Year, Department of Psychiatry and Behavioral Sciences, New York Medical College.
Dr. Citrome obtained his MD degree from the McGill University Faculty of Medicine in 1983 and his MPH degree from the Columbia School of Public Health in 1996. His immediate prior position was as the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, where he worked from 1994 through 2010 and achieved the rank of Professor of Psychiatry at the New York University School of Medicine.
Dr. Citrome is currently a consultant in clinical trial design and interpretation. He is a frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of number needed to treat and number needed to harm, and has lectured throughout the Americas, Europe, Asia, and Australasia. His main interests include schizophrenia, bipolar disorder, and major depressive disorder. He is author or coauthor of over 550 research reports, reviews, and chapters in the scientific literature. Dr. Citrome is editor emeritus, International Journal of Clinical Practice where he was editor-in-chief 2013-2019; psychiatry topic editor for Clinical Therapeutics; editor for the American Society of Clinical Psychopharmacology Corner in the Journal of Clinical Psychiatry; section editor for psychopharmacology for Current Psychiatry; and also serves as an editorial board member for CNS Spectrums, Expert Review of Neurotherapeutics, Neurology and Therapy, Clinical Psychopharmacology and Neuroscience, Annals of Clinical Psychiatry, Expert Opinion on Drug Safety, Current Drug Safety, Schizophrenia Research and Treatment, Postgraduate Medicine, Journal of Clinical Psychopharmacology, Clinical Practice, Medscape Psychiatry & Mental Health.
Philip Gorwood is a Professor of Psychiatry at Sainte-Anne Hospital, University of Paris, and Head of a team at Research Unit 1266, INSERM, Paris, France. His main topics of research are related to genetic vulnerability to psychiatric and addictive disorders.
Professor Gorwood is the immediate past president of the European Psychiatry Association (EPA), and a member of the European College of Neuropsychopharmacology scientific advisory board.
Professor Gorwood is the author or co-author of more than 300 articles published in international peer-reviewed journals, including Molecular Psychiatry, Nature Genetics, The British and the American Journal of Psychiatry, and has been quoted as the “most cited French psychiatrist” in the world (Ioannidis et al., 2019).
Philip Gorwood is a Professor of Psychiatry at Sainte-Anne Hospital, University of Paris, and Head of a team at Research Unit 1266, INSERM, Paris, France. His main topics of research are related to genetic vulnerability to psychiatric and addictive disorders.
Professor Gorwood is the immediate past president of the European Psychiatry Association (EPA), and a member of the European College of Neuropsychopharmacology scientific advisory board.
Professor Gorwood is the author or co-author of more than 300 articles published in international peer-reviewed journals, including Molecular Psychiatry, Nature Genetics, The British and the American Journal of Psychiatry, and has been quoted as the “most cited French psychiatrist” in the world (Ioannidis et al., 2019).
Professor David Castle recently took up the position of inaugural Scientific Director of the Centre for Complex Interventions at The Centre for Addiction and Mental Health, University of Toronto. Previously for 15 years he had been Professor of Psychiatry at St Vincent’s Hospital and the University of Melbourne, Australia. His clinical and research interests include schizophrenia and related disorders, and bipolar disorder. He has a longstanding interest in the impact of licit and illicit substances on the brain and body, and is actively engaged in programmes addressing the physical health of the mentally ill and the mental health of the physically ill. He is also pursuing his work on OCD spectrum disorders, notably body dysmorphic disorder. He has been successful in attracting substantial grant funding from a variety of different sources, and has strong local, national, and international research links. He has received a number of commendations for his work, including the Senior Research Award from the Royal ANZ College of Psychiatrists (RANZCP) and a University of Melbourne Vice Chancellor’s Staff Engagement Award. In 2015 he was presented with the Ian Simpson Award by the RANZCP in recognition of outstanding contributions to clinical psychiatry as assessed through service to patients and the community. He has published extensively in prestigious journal and has produced 26 books, aimed at clinical, academic and lay audiences. He is regularly invited to present at local, national and international scientific meetings. David has strong commitment to teaching, completed the Graduate Certificate in University Teaching from the University of Melbourne in 2011; was elected as a Fellow of the Melbourne Medical School Academy of Clinical Teachers in 2013; and has received teaching awards.
https://www.psychiatry.utoronto.ca/faculty/david-jonathan-castle
Professor David Castle recently took up the position of inaugural Scientific Director of the Centre for Complex Interventions at The Centre for Addiction and Mental Health, University of Toronto. Previously for 15 years he had been Professor of Psychiatry at St Vincent’s Hospital and the University of Melbourne, Australia. His clinical and research interests include schizophrenia and related disorders, and bipolar disorder. He has a longstanding interest in the impact of licit and illicit substances on the brain and body, and is actively engaged in programmes addressing the physical health of the mentally ill and the mental health of the physically ill. He is also pursuing his work on OCD spectrum disorders, notably body dysmorphic disorder. He has been successful in attracting substantial grant funding from a variety of different sources, and has strong local, national, and international research links. He has received a number of commendations for his work, including the Senior Research Award from the Royal ANZ College of Psychiatrists (RANZCP) and a University of Melbourne Vice Chancellor’s Staff Engagement Award. In 2015 he was presented with the Ian Simpson Award by the RANZCP in recognition of outstanding contributions to clinical psychiatry as assessed through service to patients and the community. He has published extensively in prestigious journal and has produced 26 books, aimed at clinical, academic and lay audiences. He is regularly invited to present at local, national and international scientific meetings. David has strong commitment to teaching, completed the Graduate Certificate in University Teaching from the University of Melbourne in 2011; was elected as a Fellow of the Melbourne Medical School Academy of Clinical Teachers in 2013; and has received teaching awards.
https://www.psychiatry.utoronto.ca/faculty/david-jonathan-castle
Dr. Timothy Wilens is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital. He is the MGH Trustees Chair in Addiction Medicine and a professor of psychiatry at Harvard Medical School.
Dr. Wilens earned his MD at the University of Michigan Medical School in Ann Arbor and completed his residency in child, adolescent and adult psychiatry at Mass General.
Dr. Wilens’ research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders; embedded health care models, and the pharmacotherapy of ADHD across the lifespan. He has published more than 300 peer-reviewed articles, concerning these and related topics. He has also coedited more than 80 book chapters, 4 books, and 300 abstracts and presentations for national and international scientific meetings.
Dr. Wilens is a distinguished fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry and is on the editorial boards or is a scientific reviewer for more than 35 journals.
Dr. Timothy Wilens is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital. He is the MGH Trustees Chair in Addiction Medicine and a professor of psychiatry at Harvard Medical School.
Dr. Wilens earned his MD at the University of Michigan Medical School in Ann Arbor and completed his residency in child, adolescent and adult psychiatry at Mass General.
Dr. Wilens’ research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders; embedded health care models, and the pharmacotherapy of ADHD across the lifespan. He has published more than 300 peer-reviewed articles, concerning these and related topics. He has also coedited more than 80 book chapters, 4 books, and 300 abstracts and presentations for national and international scientific meetings.
Dr. Wilens is a distinguished fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry and is on the editorial boards or is a scientific reviewer for more than 35 journals.
Dr. Gagan Joshi is the Director of the Autism Spectrum Disorders Program in the Pediatric Psychopharmacology Clinical and Research Program and Medical Director of the Bressler Program at Massachusetts General Hospital. He is an Assistant Professor of Psychiatry at Harvard Medical School.
Dr. Joshi trained in General Psychiatry at the Hospital of the University of Pennsylvania and subsequently completed his Fellowship training in Child and Adolescent Psychiatry at the combined program of Massachusetts General Hospital and McLean Hospital, Harvard Medical School. He received training in cognitive-behavioral therapy at the Beck Institute for Cognitive Therapy and trained in psychodynamic psychotherapy at the Philadelphia Psychoanalytic Institute & Society.
Dr. Joshi has been the recipient of the prestigious Ethel Dupont Warren Fellowship Award through the Department of Psychiatry at Harvard Medical School. He is also the recipient of the Collegium Internationale Neuro-Psychopharmalogicum Congress Young Investigators Award and the American Academy of Child and Adolescent Psychiatry Pilot Research Award. Dr. Joshi is the current Norma Fine Fellowship recipient.
Dr. Joshi's clinical and research interest is in Autism Spectrum Disorders (ASD) with particular focus on the often-neglected comorbid conditions associated with ASD. In addition to coordinating the Bressler clinic and providing clinical care to individuals with ASD, Dr. Joshi is facilitating the expansion of research in autism and related comorbidities in the Pediatric Psychopharmacology Clinical and Research Program at MGH. He has developed specific research projects examining the clinical, genetic, and neural underpinnings and treatment of high functioning ASD and associated psychiatric conditions.
Dr. Gagan Joshi is the Director of the Autism Spectrum Disorders Program in the Pediatric Psychopharmacology Clinical and Research Program and Medical Director of the Bressler Program at Massachusetts General Hospital. He is an Assistant Professor of Psychiatry at Harvard Medical School.
Dr. Joshi trained in General Psychiatry at the Hospital of the University of Pennsylvania and subsequently completed his Fellowship training in Child and Adolescent Psychiatry at the combined program of Massachusetts General Hospital and McLean Hospital, Harvard Medical School. He received training in cognitive-behavioral therapy at the Beck Institute for Cognitive Therapy and trained in psychodynamic psychotherapy at the Philadelphia Psychoanalytic Institute & Society.
Dr. Joshi has been the recipient of the prestigious Ethel Dupont Warren Fellowship Award through the Department of Psychiatry at Harvard Medical School. He is also the recipient of the Collegium Internationale Neuro-Psychopharmalogicum Congress Young Investigators Award and the American Academy of Child and Adolescent Psychiatry Pilot Research Award. Dr. Joshi is the current Norma Fine Fellowship recipient.
Dr. Joshi's clinical and research interest is in Autism Spectrum Disorders (ASD) with particular focus on the often-neglected comorbid conditions associated with ASD. In addition to coordinating the Bressler clinic and providing clinical care to individuals with ASD, Dr. Joshi is facilitating the expansion of research in autism and related comorbidities in the Pediatric Psychopharmacology Clinical and Research Program at MGH. He has developed specific research projects examining the clinical, genetic, and neural underpinnings and treatment of high functioning ASD and associated psychiatric conditions.
Andrea Fagiolini graduated from Liceo Scientifico (60/60) in Livorno (Italy) and received his medical training in Italy at the University of Pisa (Italy) School of Medicine (110/110 lode). After completing his psychiatric residency (70/70 lode) at the University of Modena (Italy), he spent more than 10 years on the faculty of the University of Pittsburgh Medical School (USA), where he served as Associate Professor of Psychiatry and Medical Director of the Bipolar Disorder Center and of the Depression and Manic Depression Prevention Program. He then joined the faculty of the University of Siena School of Medicine, where he presently serves as Professor of Psychiatry, medical director and residency training director of the Division of Psychiatry in the Department of Molecular Medicine. He also serves as Chairman of the Department of Mental Health (DAI) in the University of Siena Medical Center (AOUS). He has published over 400 papers and book chapters and seats in the Editorial Board of several peer reviewed international journals. He is principal investigator or co-investigator in several internationally funded research studies (mainly phase 3 trials). His research interests and publications have primarily focused on the treatment of mood and anxiety disorders, suicidality, functional impairment and quality of life in patients with mental diseases.
Andrea Fagiolini graduated from Liceo Scientifico (60/60) in Livorno (Italy) and received his medical training in Italy at the University of Pisa (Italy) School of Medicine (110/110 lode). After completing his psychiatric residency (70/70 lode) at the University of Modena (Italy), he spent more than 10 years on the faculty of the University of Pittsburgh Medical School (USA), where he served as Associate Professor of Psychiatry and Medical Director of the Bipolar Disorder Center and of the Depression and Manic Depression Prevention Program. He then joined the faculty of the University of Siena School of Medicine, where he presently serves as Professor of Psychiatry, medical director and residency training director of the Division of Psychiatry in the Department of Molecular Medicine. He also serves as Chairman of the Department of Mental Health (DAI) in the University of Siena Medical Center (AOUS). He has published over 400 papers and book chapters and seats in the Editorial Board of several peer reviewed international journals. He is principal investigator or co-investigator in several internationally funded research studies (mainly phase 3 trials). His research interests and publications have primarily focused on the treatment of mood and anxiety disorders, suicidality, functional impairment and quality of life in patients with mental diseases.